Assessment and monitoring of glycemic control in children and adolescents with diabetes

Pediatric Diabetes

Volumn 10, Issue SUPPL. 12, 2009, Pages 71-81

  Rewers, Marian ^a   Pihoker, Catherine ^b   Donaghue, Kim ^c   Hanas, Ragnar ^d   Swift, Peter ^e   Klingensmith, Georgeanna J ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b Children's Hospital and Medical Center   (United States)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UDDEVALLA HOSPITAL   (Sweden)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; KETONE;

ADOLESCENT; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC DIET; DOCUMENTATION; DRUG DOSE TITRATION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN PUMP; KETOACIDOSIS; KETONURIA; MICROANGIOPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SELF MONITORING;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; GLYCOSURIA; HOMEOSTASIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KETONE BODIES; MONITORING, AMBULATORY; MONITORING, PHYSIOLOGIC; OUTCOME ASSESSMENT (HEALTH CARE); VASCULAR DISEASES;

EID: 70350143585     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2009.00582.x     Document Type: Article

References (94)

1. The Diabetes Control and Complications Trialresearch Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group [see comment]. J Pediatr 1994: 125: 177-188.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [see comment]. N Engl J Med 1993: 329: 977-986.
3. De Beaufort CE, Swift PG, Skinner CT et al. Continuing stability of center differences in pediatric diabetes care: Do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care 2007: 30: 2245-2250.
4. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008: 570: 995-1001.
5. DCCT/EDIC Research Group. Modern-Day Clinical Course of Type 1 Diabetes Mellitus. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Experience. American Diabetes Association 2007: Report No.: Abstract 0996-P Diabetes 207: 56 (Suppl. 1): A260, 996-P.
6. White NH, Cleary PA, Dahms W et al. Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT) [see comment]. J Pediatr 2001: 139: 804-812.
7. Mohsin F, Craig ME, Cusumano J et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care 2005: 28: 1974-1980.
8. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [see comment]. N Engl J Med 2005: 353: 2643-2653.
9. Orchard TJ, Forrest KY, Kuller LH, Becker DJ; Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabeteions Study. Diabetes Care 2001: 24: 1053-1059.
10. Danne T, Weber B, Hartmann R, Enders I, Burger W, Hovener G. Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Follow-up of the Berlin Retinopathy Study. Diabetes Care 1994: 17: 1390-1396.
11. Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: A longitudinal study. Diabetes Care 2003: 26: 1052-1057.
12. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications. N Engl J Med 2000: 10: 381-389 (Erratum appears in: N Engl J Med 2000: 342: 1376).
13. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology Ofdiabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003: 290: 2159-2167.
14. Donaghue KC, Fung AT, Hing S et al. The effect of prepubertal diabetes duration on diabetes. Microvascular complications in early and late adolescence. Diabetes Care 1997: 20: 77-80.
15. Anderson B, Ho J, Brackett J, Finkelstein D, Laffel L. Parental involvement in diabetes management tasks: Relationships to blood glucose monitoring adherence and metabolic control in young adolescents with insulindependent diabetes mellitus. J Pediatr 1997: 130: 257-265.
16. Svoren BM, Volkening LK, Butler DA, Moreland EC, Anderson BJ, Laffel LM. Temporal trends in the treatment of pediatric type 1 diabetes and impact on acute outcomes. J Pediatr 2007: 150: 279-285.
17. Nathan DM,Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus [see comment]. N Engl J Med 2003: 348: 2294-2303.
18. Diliberti JH,Lorenz RA. Long-term trends in childhood diabetes mortality: 1968-1998. Diabetes Care 2001: 24: 1348-1352.
19. Nishimura R, Laporte RE, Dorman JS, Tajima N, Becker D, Orchard TJ. Mortality trends in type 1diabetes. The Allegheny County (Pennsylvania) Registry 1965-1999 [see comment]. Diabetes Care 2001: 24: 823-827.
20. Sovik O, Thordarson H. Dead-in-bed syndrome in young diabetic patients. Diabetes Care 1999: 22 (Suppl. 2): B40-B42 (Erratum appears in: Diabetes Care 1999: 22: 1389).
21. W eston PJ, G ill GV. Is undetected autonomic dysfunction responsible for sudden death in type 1 diabetes mellitus? The_dead in bed'syndrome revisited [see comment]. Diabet Med 1999: 16: 626-631 (Review).
22. Eeg-Olofsson O, Petersen I. Childhood diabetic neuropathy. A clinical and neurophysiological study. Acta Paediatr 2001: 55: 163-176.
23. Gilhaus KH, Daweke H, Lulsdorf HG, Sachsse R, Sachsse B. [EEG changes in diabetic children] [German]. Dtsch Med Wochenschr 1973: 98: 1449-1454.
24. Ryan CM, Williams TM, Finegold DN, Orchard TJ. Cognitive dysfunction in adults with type 1 (insulindependent) diabetes mellitus of long duration: Effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 1993: 36: 329-334.
25. Schlack H, Palm D, Jochmus I. [Influence of recurrent hypoglycemia on the EEG of the diabetic child] [German]. Monatsschr Kinderheilkd 1969: 117: 251-253.
26. Soltesz G, Acsadi G. Association between diabetes, severe hypoglycaemia, and electroencephalographic abnormalities. Arch Dis Child 1989: 64: 992-996.
27. Strudwick SK, Carne C,Gardiner J,Foster JK, Davis EA, Jones TW. Cognitive functioning in children with early onset type 1 diabetes and severe hypoglycemia. J Pediatr 2005: 147: 680-685.
28. Davis EA, Jones TW. Hypoglycemia in children with diabetes: Incidence, counterregulation and cognitive dysfunction. J Pediatr Endocrinol Metab 1998: 11 (Suppl. 1): 177-182 (Review).
29. Wysocki T, Harris MA, Mauras N et al. Absence of adverse effects of severe hypoglycemia on cognitive function in school-aged children with diabetes over 18 months. Diabetes Care 2003: 26: 1100-1105.
30. Austin EJ, Deary IJ. Effects of repeated hypoglycemia on cognitive function: A psychometrically validated reanalysis of the Diabetes Control and Complications Trial data. Diabetes Care 1999: 22: 1273-1277.
31. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007: 356: 1842-1852.
32. Tupola S, Rajantie J, Akerblom HK. Experience of severe hypoglycaemia may influence both patient's and physician's subsequent treatment policy of insulindependent diabetes mellitus. Eur J Pediatr 1998: 157: 625-627.
33. Schoenle EJ, Schoenle D, Molinari L, Largo RH. Impaired intellectual development in children with type I diabetes: Association with HbA1c, age at diagnosis and sex. Diabetologia 2002: 45: 108-114.
34. Cox DJ, Kovatchev BP, Gonder-Frederick LA et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 2005: 28: 71-77.
35. Davis EA, Soong SA, Byrne GC, Jones TW. Acute hyperglycaemia impairs cognitive function in children with IDDM. J Pediatr Endocrinol Metab 1996: 9: 455-461.
36. Martin DD, Davis EA, Jones TW. Acute effects of hyperglycaemia in children with type 1 diabetes mellitus: The patient's perspective. J Pediatr Endocrinol Metab 2006: 19: 927-936.
37. Perantie DC, Wu J, Koller JM et al. Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care 2007: 30: 2331-2337.
38. Musen G, Lyoo IK, Sparks CR et al. Effects of type 1 diabetes on gray matter density as measured by voxelbased morphometry. Diabetes 2006: 55: 326-333.
39. Ryan CM. Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis. Pediatr Diabetes 2006: 7: 289-97.
40. Schiffrin A, Belmonte M. Multiple daily self-glucose monitoring: Its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care 1982: 5: 479-484.
41. Haller MJ, Stalvey MS, Silverstein JH. Predictors of control of diabetes: Monitoring may be the key. J Pediatr 2004: 144: 660-661.
42. Levine BS, Anderson BJ, Butler DA, Antisdel JE, Brackett J, Laffel LM. Predictors of glycemic control and short-term adverse outcomes in youth with type 1 diabetes [see comment]. J Pediatr 2001: 139: 197-203.
43. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003: 26: 1142-1146.
44. Schneider S, Iannotti RJ, Nansel TR et al. Identification of distinct self-management styles of adolescents with type 1 diabetes. Diabetes Care 2007: 30: 1107-1112.
45. Weinzimer SA, Ahern JH, Doyle EA et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: A follow-up report. Pediatrics 2004: 114: 1601-1605 (Erratum appears in: Pediatrics 2005: 115: 518).
46. Diabetes Research in Children Network (Direcnet) Study Group, Tsalikian E, Kollman C et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care 2006: 29: 2200-2204.
47. Jungheim K, Koschinsky T. Glucose monitoring at the arm: Risky delays of hypoglycemia and hyperglycemia detection. Diabetes Care 2002: 25: 956-960.
48. Lucidarme N, Alberti C, Zaccaria I, Claude E, Tubiana-Rufi N. Alternate-site testing is reliable in children and adolescents with type 1 diabetes, except at the forearm for hypoglycemia detection. Diabetes Care 2005: 28: 710-711.
49. Bergenstal R, Pearson J, Cembrowski GS, Bina D, Davidson J, List S. Identifying variables associated with inaccurate self-monitoring of blood glucose: Proposed guidelines to improve accuracy. Diabetes Educ 2000: 26: 981-989.
50. Tsalikian E, Mauras N, Beck RW et al. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr 2005: 147: 528-534.
51. Tansey MJ, Tsalikian E, Beck RW et al. The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care 2006: 29: 20-25.
52. Hermansson G, Ludvigsson J, Larsson Y. Home blood glucose monitoring in diabetic children and adolescents. A 3-year feasibility study. Acta Paediatr Scand 1986: 75: 98-105.
53. Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene. Diabet Med 1998: 15: 816-820.
54. Halvorson M, Carpenter S, Kaiserman K, Kaufman FR. A pilot trial in pediatrics with the sensoraugmented pump: Combining real-time continuous glucose monitoring with the insulin pump. J Pediatr 2007: 150: 103-105.
55. Mastrototaro JJ, Cooper KW, Soundararajan G, Sanders JB, Shah RV. Clinical experience with an integrated continuous glucose sensor/insulin pump platform: A feasibility study. Adv Ther 2006: 23: 725-732.
56. Chase HP, Kim LM, Owen SL et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes [see comment]. Pediatrics 2001: 107: 222-226.
57. Garg S, Zisser H, Schwartz S et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: A randomized controlled trial. Diabetes Care 2006: 29: 44-50.
58. Heptulla RA, Allen HF, Gross TM, Reiter EO. Continuous glucose monitoring in children with type 1 diabetes: Before and after insulin pump therapy. Pediatr Diabetes 2004: 5: 10-15.
59. Wentholt IM, Maran A, Masurel N, Heine RJ, Hoekstra JB, Devries JH. Nocturnal hypoglycaemia in type 1 diabetic patients, assessed with continuous glucose monitoring: Frequency, duration and associations. Diabet Med 2007: 24: 527-532.
60. Deiss D, Bolinder J, Riveline JP et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006: 29: 2730-2732.
61. Iscoe KE, Campbell JE, Jamnik V, Perkins BA, Riddell MC. Efficacy of continuous real-time blood glucose monitoring during and after prolonged highintensity cycling exercise: Spinning with a continuous glucose monitoring system. Diabetes Technol Ther 2006: 8: 627-635.
62. Maia FF, Araujo LR. [Accuracy, utility and complications of continuous glucose monitoring system (CGMS) in pediatric patients with type 1 diabetes] [see comment] [Portuguese]. J Pediatr 2005: 81: 293-297.
63. Mozdzan M, Ruxer J, Loba J, Siejka A, Markuszewski L. Safety of various methods of intensive insulin therapy in hospital condition assessed by hypoglycaemic episodes detected with the use of continuous glucose monitoring system. Adv Med Sci 2006: 51: 133-136.
64. Sparacino G, Zanderigo F, Corazza S, Maran A, Facchinetti A, Cobelli C. Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series. IEEE Trans Biomed Eng 2007: 54: 931-937.
65. Diabetes Research in Children Network Study Group, Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes 2009: 10 (2): 91-6.
66. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'GradyM, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008: Oct 2; 359 (14): 1464-76.
67. Laffel LM, Wentzell K, Loughlin C, Tovar A, Moltz K, Brink S. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: A randomized clinical trial. Diabet Med 2006: 23: 278-284.
68. Rewers A, Mcfann K, Chase HP. Bedside monitoring of blood beta-hydroxybutyrate levels in the management of diabetic ketoacidosis in children. Diabetes Technol Ther 2006: 8: 671-676.
69. Rewers A,Chase HP, Mackenzie T et al. Predictors of acute complications in children with type 1 diabetes. JAMA 2002: 287: 2511-2518 (Summary for patients in: J Pediatr 2002: 141: 739-740; PMID: 12448434).
70. Guerci B, Benichou M, Floriot M et al. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care 2003: 26: 1137-1141.
71. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level [see comment]. Diabetes Care 1995: 18: 440-447.
72. Diabetes Research in Children Network Study Group. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: Results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes 2005: 6: 13-16.
73. Chase HP, Lockspeiser T, Peery B et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001: 24: 430-434.
74. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child 1998: 78: 111-115.
75. Nordfeldt S, Ludvigsson J. Adverse events in intensively treated children and adolescents with type 1 diabetes. Acta Paediatr 1999: 88: 1184-1193.
76. Mitrakou A, Ryan C, Veneman T et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991: 260: E67-E74.
77. Fanelli C, Pampanelli S, Epifano L et al. Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans. Diabetologia 1994: 37: 797-807.
78. Davis SN, Shavers C, Mosqueda-Garcia R, Costa F. Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes 1997: 46: 1328-1335.
79. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002: 45: 937-948 (Review).
80. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991: 40: 223-226.
81. Jones TW, Borg WP, Borg MA et al. Resistance to neuroglycopenia: An adaptive response during intensive insulin treatment of diabetes. J Clin Endocrinol Metab 1997: 82: 1713-1718.
82. Simonson DC, Tamborlane WV, Defronzo RA, Sherwin RS. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Ann InternMed 1985: 103: 184-190.
83. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994: 344: 283-287.
84. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 1994: 17: 734-755 (Review).
85. Bober E, Buyukgebiz A. Hypoglycemia and its effects on the brain in children with type 1 diabetes mellitus. Pediatr Endocrinol Rev 2005: 2: 378-382 (Review).
86. Desrocher M, Rovet J. Neurocognitive correlates of type 1 diabetes mellitus in childhood. Child Neuropsychol 2004: 10: 36-52 (Review).
87. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c [see comment]. JAMA 2006: 295: 1688-1697 (Review).
88. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) IFCC Scientific Division, Mosca AGoodall I HTJJJWLRMKMGRHSDWC. Global standardization of glycated hemoglobin measurement: The position of the IFCC Working Group. Clin Chem Lab Med 2007: 45: 1077-1080.
89. Report of the ADA/EASD/IDF Working Group of the HbA1c Assay, London, UK: January. Diabetologia 2004: 47: R53-R54.
90. Hoelzel W, Miedema K. Development of a reference system for the international standardization of HbA1c/glycohemoglobin determinations. J Int Fed Clin Chem 1966: 9: 62-64 (Review).
91. Kobold U, Jeppsson JO, Dulffer T, Finke A, Hoelzel W, Miedema K. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 1997: 43: 1944-1951.
92. Hoelzel W, Weykamp C, Jeppsson JO et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A methodcomparison study. Clin Chem 2004: 50: 166-174.
93. sacks DB, for the ADA/EASD/IDF Working Group of the HbA. Global harmonization of hemoglobin A1c. Clin Chem 2005: 51: 681-683.
94. Nathan DM, Kvenen J,Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008: 31: 1473-1478.